Description

According to a report by StrategyHelix, the global high content screening market is set to increase by US$ 839.4 million during 2022-2028, growing at a CAGR of 9.2% during the forecast period.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for high content screening. The global high content screening market is segmented on the basis of component, application, end user, and region. On the basis of component, the global high content screening market has been segmented into consumables (reagents and kits), instrument or platform, services, software and analytics. The instrument or platform segment held the largest revenue share in 2021. By application, the global high content screening market has been segmented into compound profiling, drug discovery, molecular diagnosis, oncology, toxicity studies, others. Among these, the drug discovery segment was accounted for the highest revenue generator in 2021. Based on end user, the global high content screening market is categorized into academic institutions, laboratories and pathology centers, pharmaceutical and biotechnology companies. The pharmaceutical and biotechnology companies segment captured the largest share of the market in 2021. Geographically, the global high content screening market is segmented into Asia Pacific, Europe, North America, Rest of the World (RoW).

The instrument market is further segmented into cytometers, detectors and sensors, imaging devices, liquid handling instruments, plate readers, and others. Globally, the imaging devices segment made up the largest share of the high content screening market.

The global high content screening market is highly competitive. The prominent players operating in the global high content screening market include Agilent Technologies Inc., Bio-Rad Laboratories Inc., Danaher Corp., GE Healthcare, Merck KGaA, Olympus Corporation, PerkinElmer Inc., Sartorius AG, Thermo Fisher Scientific Inc., Yokogawa Electric Corporation.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the high content screening market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Component: consumables (reagents and kits), instrument or platform, services, software and analytics
Application: compound profiling, drug discovery, molecular diagnosis, oncology, toxicity studies, others
End user: academic institutions, laboratories and pathology centers, pharmaceutical and biotechnology companies
Region: Asia Pacific, Europe, North America, Rest of the World (RoW)
Years considered: this report covers the period 2018 to 2028

Key Benefits for Stakeholders

– Get a comprehensive picture of the global high content screening market
– Pinpoint growth sectors and trends for investment

Table of Contents

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. High content screening market overview
Part 3. Market breakdown by component
– Consumables (reagents and kits)
– Instrument or platform
– Services
– Software and analytics
Part 4. Market breakdown by application
– Compound profiling
– Drug discovery
– Molecular diagnosis
– Oncology
– Toxicity studies
– Others
Part 5. Market breakdown by end user
– Academic institutions
– Laboratories and pathology centers
– Pharmaceutical and biotechnology companies
Part 6. Market breakdown by region
– Asia Pacific
– Europe
– North America
– Rest of the World (RoW)
Part 7. Key companies
– Agilent Technologies Inc.
– Bio-Rad Laboratories, Inc.
– Danaher Corp.
– GE Healthcare
– Merck KGaA
– Olympus Corporation
– PerkinElmer, Inc.
– Sartorius AG
– Thermo Fisher Scientific Inc.
– Yokogawa Electric Corporation
About StrategyHelix
Disclaimer